Sunday, March 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Path to Herd Immunity

COVID-19 Projections machine learning team cites the following notes in their live analysis of herd immunity in the United States.

Key briefing notes include:

Path to Herd Immunity: 2021 Outlook of COVID-19 in the US

We estimate COVID-19 herd immunity (>70% of population immune) will be reached in the US during summer 2021 (Jun-Aug 2021). At a high level, herd immunity is a concept in which a population can be protected from a virus if enough people possess immunity.

At the time herd immunity is reached, roughly half of the immunity will be achieved through natural infection, and the other half will be achieved through vaccination.

New infections may become minimal before herd immunity is reached. But due to imported cases and localized clusters, it is unlikely that new infections will drop to zero until at least 2022.

Deaths may drop to low levels even earlier (May-Jul 2021), in part due to a vaccine distribution strategy that initially prioritizes high-risk individuals. Once deaths fall to minimal levels, we may see a relaxation of restrictions.

Summarizing the above findings, our best estimate of a complete “return to normal” in the US is mid-summer 2021 (June/July 2021).

We estimate roughly 80% of the US population (~265 million) will receive at least one dose of the vaccine by the end of 2021, with children and adolescents being the last group to receive it (Aug-Nov 2021).

We estimate around 35% of the US population (~120 million) will have been infected by the SARS-CoV-2 virus by the end of 2021. That is an additional 55 million infections since mid-December 2020.

This translates to a final US COVID-19 death toll of roughly 600,000 (±100,000) reported deaths, or ~300,000 additional deaths since mid-December 2020.

Source: COVID-19 Projections

https://covid19-projections.com/path-to-herd-immunity/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!